Shaperon Inc.
Founded in 2008 and KOSDAQ-listed in 2022, Shaperon runs a GPCR19-targeted inflammasome inhibitor platform and a nanomab antibody platform.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureShaperon Inc. was founded in 2008 and listed on KOSDAQ in 2022, operating a GPCR19-targeted inflammasome inhibitor platform and a nanomab antibody development platform. Its lead pipeline includes NuSepin, a COVID-19 pneumonia treatment, alongside candidates for atopic dermatitis and Alzheimer's dementia. NuSepin completed a Phase 2 trial at five centers in Romania and a multinational Phase 2b trial backed by KRW 9.1 billion from the Korea Drug Development Fund (KDDF); the atopic dermatitis candidate received FDA IND approval in September 2023 and is in Phase 2b, the Alzheimer's candidate is in domestic Phase 1, and the company has completed two technology transfer deals.
Products & technology
- NuSepinCOVID-19 pneumonia and cardiopulmonary bypass-induced respiratory failure treatment
Clinical trials
data.go.kr6 MFDS clinical trial authorisations · 2012–2025 (Phase 1 3 · Phase 2 2 · Phase 2b/3 1)
- Phase 2HY2092025-02-04
4 trial sites
- Phase 2b/3HY209주2022-01-11
17 trial sites
- Phase 2HY2092020-06-19
5 trial sites
- Phase 1HY209주2019-05-13
2 trial sites
- Phase 1HY-209겔2016-12-12
1 trial site
- Phase 1HY-209 주사제2012-11-23
1 trial site
R&D and key agreements
Source: DART corporate disclosureNuSepin · COVID-19 폐렴 · 임상2상 완료(루마니아 5개 센터, EMA승인, 2021), 다국적 임상2b상 완료 · Multinational Phase 2b trial completed with KRW 9.1bn KDDF funding
아토피 · FDA IND 승인(2023.09), 임상2b상 진행중 · FDA IND approval for atopic dermatitis candidate
알츠하이머 치매 · 국내 임상1상 진행중 · Domestic Phase 1 trial for Alzheimer's dementia candidate
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition